N-Myc expression enhances the oncolytic effects of vesicular stomatitis virus in human neuroblastoma cells

Corredor, Juan Carlos; Redding, Nicole; Blote, Karen; Robbins, Stephen M.; Senger, Donna L.; Bell, John C.; Beaudry, Paul

doi:10.1038/mto.2016.5

Cited by 3 publications

(2 citation statements)

References 69 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…N-Myc overexpression has been shown to enhance VSV replication and oncolysis in human neuroblastoma cells due to inhibition of ISGs [78]. Oncogenic Ras has been shown to promote VSVmediated oncolysis due to inhibition of IRF1 [79].…”

Section: Other Approaches To Improve Vsv Oncoselectivitymentioning

confidence: 99%

Recent advances in vesicular stomatitis virus-based oncolytic virotherapy: a 5-year update

Felt

Grdzelishvili

2017

Journal of General Virology

View full text Add to dashboard Cite

Oncolytic virus (OV) therapy is an anti-cancer approach that uses viruses that preferentially infect, replicate in and kill cancer cells. Vesicular stomatitis virus (VSV, a rhabdovirus) is an OV that is currently being tested in the USA in several phase I clinical trials against different malignancies. Several factors make VSV a promising OV: lack of pre-existing human immunity against VSV, a small and easy to manipulate genome, cytoplasmic replication without risk of host cell transformation, independence of cell cycle and rapid growth to high titres in a broad range of cell lines facilitating large-scale virus production. While significant advances have been made in VSV-based OV therapy, room for improvement remains. Here we review recent studies (published in the last 5 years) that address 'old' and 'new' challenges of VSV-based OV therapy. These studies focused on improving VSV safety, oncoselectivity and oncotoxicity; breaking resistance of some cancers to VSV; preventing premature clearance of VSV; and stimulating tumour-specific immunity. Many of these approaches were based on combining VSV with other therapeutics. This review also discusses another rhabdovirus closely related to VSV, Maraba virus, which is currently being tested in Canada in phase I/II clinical trials.

show abstract

Section: Other Approaches To Improve Vsv Oncoselectivitymentioning

confidence: 99%

Recent advances in vesicular stomatitis virus-based oncolytic virotherapy: a 5-year update

Felt

Grdzelishvili

2017

Journal of General Virology

View full text Add to dashboard Cite

show abstract

“…In recent years, research has showed that the MYCN gene is an indicator of NB with aggressive progression and a poor prognosis [12,13] . Wang [14] reported that 12% of children with NB had MYCN amplification.…”

Section: Discussionmentioning

confidence: 99%

Clinical characteristics and prognosis of 40 patients with periorbital metastasis of neuroblastoma

Qin

Zhao

Jin

et al. 2020

Preprint

View full text Add to dashboard Cite

BackgroundThis study was performed to summarize the clinical characteristics of patients with periorbital metastasis of neuroblastoma (NB) and analyze the short-term prognosis. MethodsThis study included 40 patients with periorbital metastasis of NB from March 2007 to March 2018. The patients' clinical characteristics and short-term prognosis were retrospectively analyzed. ResultsThe 40 patients comprised 25 boys and 15 girls with a median age at onset of 31 months (range, 8-132 months). The patients' symptoms included a periorbital mass and eye bruising (n = 37, 92.5%), limb pain (n = 14, 35.0%), a head and neck mass (n = 8, 20.0%), fever (n = 8, 20.0%), an abdominal mass (n = 4, 10.0%), weakness (n = 3, 7.5%), abdominal pain (n = 2, 5.0%), anemia (n = 2, 5.0%), and others (n = 3, 7.5%). All 40 patients had stage IV, high-risk NB. Various auxiliary structures of the eye were involved: ocular muscles (n = 11, 27.5%), lacrimal glands (n = 4, 10.0%), optic nerve (n = 2, 5.0%), and eyelid (n = 1 2.5%). Fifteen patients (37.5%) had tumor invasion in a periorbital sinus cavity. All patients had bone marrow and bone metastasis. Of 38 patients with a known MYCN gene status, 17 patients (44.7%) had MYCN amplification. The median follow-up duration was 19 months

show abstract

Progress of oncolytic virotherapy for neuroblastoma

Chen

Dai²,

Zhan³

et al. 2022

Front. Pediatr.

View full text Add to dashboard Cite

As a neuroendocrine tumor derived from the neural crest, neuroblastoma (NB) is the most common extracranial solid tumor in children. The prognosis in patients with low- and intermediate-risk NB is favorable while that in high-risk patients is often detrimental. However, the management of the considerably large proportion of high-risk patients remains challenging in clinical practice. Among various new approaches, oncolytic virus (OV) therapy offers great advantages in tumor treatment, especially for high-risk NB. Genetic modified OVs can target NB specifically without affecting normal tissue and avoid the widespread drug resistance issue in anticancer monotherapy. Meanwhile, its safety profile provides great potential in combination therapy with chemo-, radio-, and immunotherapy. The therapeutic efficacy of OV for NB is impressive from bench to bedside. The effectiveness and safety of OVs have been demonstrated and reported in studies on children with NB. Furthermore, clinical trials on some OVs (Celyvir, Pexa-Vec (JX-594) and Seneca Valley Virus (NTX-010)) have reported great results. This review summarizes the latest evidence in the therapeutic application of OVs in NB, including those generated in cell lines, animal models and clinical trials.

show abstract

N-Myc expression enhances the oncolytic effects of vesicular stomatitis virus in human neuroblastoma cells

Cited by 3 publications

References 69 publications

Recent advances in vesicular stomatitis virus-based oncolytic virotherapy: a 5-year update

Recent advances in vesicular stomatitis virus-based oncolytic virotherapy: a 5-year update

Clinical characteristics and prognosis of 40 patients with periorbital metastasis of neuroblastoma

Progress of oncolytic virotherapy for neuroblastoma

Contact Info

Product

Resources

About